Sjogren’s is not a simple disease. Nearly 40% of patients develop organ involvement, and the risk of lymphoma is 15 to 20 times that of the general population. It’s also a disease that’s often oversimplified as "just dryness"—even by rheumatologists.
Over the course of five groundbreaking episodes, you’ll hear from the world’s leading Sjogren’s experts, who will decode what every clinician needs to know: what Sjogren’s really looks like, what’s routinely being missed, and why over the next couple of years, everything is going to change.
This content is intended for medical professionals only.
All content for Decoding Sjogren’s Disease: A Clinical Deep Dive is the property of Health Monitor Network and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Sjogren’s is not a simple disease. Nearly 40% of patients develop organ involvement, and the risk of lymphoma is 15 to 20 times that of the general population. It’s also a disease that’s often oversimplified as "just dryness"—even by rheumatologists.
Over the course of five groundbreaking episodes, you’ll hear from the world’s leading Sjogren’s experts, who will decode what every clinician needs to know: what Sjogren’s really looks like, what’s routinely being missed, and why over the next couple of years, everything is going to change.
This content is intended for medical professionals only.
Innovation is Coming: The Next Era in Sjogren’s Treatment
Decoding Sjogren’s Disease: A Clinical Deep Dive
21 minutes
1 month ago
Innovation is Coming: The Next Era in Sjogren’s Treatment
In this episode, we look to the future of Sjogren’s care—one that’s more personalized, precise, and full of hope. We talk through how the condition is managed today and map out the key patient phenotypes, as well as explore breakthrough treatments now in late-stage trials, explaining how the next five years could transform how we treat this complex disease.
About Dr. Nancy Carteron
Dr. Carteron is a Professor at the University of California, Berkeley, and the immediate past chair of the Medical and Scientific Advisory group of the Sjogren’s Foundation. She currently sees patients at the Interdisciplinary Sjogren’s Clinic at UC Berkeley. She is a nationally recognized leader in clinical innovation and research for Sjögren’s disease.
In this episode, we explore:
(00:00) Patient-centric Sjogren's diagnosis strategy
(05:21) Lymphoproliferative risks in Sjogren's
(08:49) Sjogren's: fatigue, brain fog, inflammation
(10:45) Late-stage clinical trials with therapies designed specifically for Sjogren’s
(11:50) Targeting pathways in autoimmunity
(14:28) Undetected antibodies in Sjogren's disease
(17:51) If you take one thing from this episode...
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Decoding Sjogren’s Disease: A Clinical Deep Dive
Sjogren’s is not a simple disease. Nearly 40% of patients develop organ involvement, and the risk of lymphoma is 15 to 20 times that of the general population. It’s also a disease that’s often oversimplified as "just dryness"—even by rheumatologists.
Over the course of five groundbreaking episodes, you’ll hear from the world’s leading Sjogren’s experts, who will decode what every clinician needs to know: what Sjogren’s really looks like, what’s routinely being missed, and why over the next couple of years, everything is going to change.
This content is intended for medical professionals only.
